Form 4: Allogene Therapeutics SVP Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics, sold 5,488 shares of common stock on March 14, 2025, to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 14, 2025, Benjamin Machinas Beneski, SVP and Chief Technical Officer of Allogene Therapeutics, sold 5,488 shares of Allogene Therapeutics common stock.
- The sale was executed at a price of $1.975 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units, as mandated by the Issuer's equity incentive plan.
- Following the transaction, Beneski directly owns 218,507 shares of Allogene Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction to cover tax obligations. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction appears to be related to tax obligations and not necessarily indicative of a change in sentiment regarding the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of stock sale transaction |
| 03/18/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.